Dizhe Pharmaceutical (688192.SH) announced, recently, the Drug Evaluation Center of the State Drug Administration (“C...
Zhitong Financial App News, Dizhe Pharmaceutical (688192.SH) announced that recently, the Drug Evaluation Center of the State Drug Administration (“CDE”) granted the company Breakthrough Therapy Designation (BTD) as the first self-developed novel lung cancer target drug, Shuvozhe (generic name: sulvortinib tablets) for local progression or metastasis of EGFR (EGFR) exon insertion mutation (exon20InS) without systematic treatment non-small cell lung cancer (NSCLC).